By Prime Law Hub 
The Empower Pharmacy lawsuit centers on allegations by pharmaceutical manufacturer Eli Lilly and Company that Houston-based Empower Clinic Services, LLC, doing business as Empower Pharmacy, unlawfully compounded and marketed versions of tirzepatide, the active ingredient in Lilly’s FDA-approved drugs Mounjaro and Zepbound. Filed in federal court, the case raises questions about the boundaries between traditional pharmacy compounding and large-scale drug manufacturing, as well as consumer protection in the marketing of compounded medications.
This legal dispute has drawn attention because it involves popular GLP-1 receptor agonist medications used for type 2 diabetes and weight management. Many patients turned to compounded alternatives during national shortages. With the shortages resolved, regulators and brand manufacturers have increased scrutiny of compounding practices. The lawsuit highlights tensions between patient access to affordable treatments and requirements for drug safety, efficacy, and quality oversight.
Background and Legal Context
Compounding pharmacies prepare customized medications for individual patients when commercially available drugs do not meet specific needs, such as dosage adjustments or allergen avoidance. Federal law governs these activities through the Federal Food, Drug, and Cosmetic Act (FDCA), particularly sections 503A and 503B, added by the Drug Quality and Security Act of 2013 following a deadly fungal meningitis outbreak linked to contaminated compounded steroids.
Under section 503A, traditional compounding pharmacies may create patient-specific drugs pursuant to a valid prescription, but they cannot engage in large-scale manufacturing or copy FDA-approved drugs when those drugs are not in shortage. Section 503B applies to outsourcing facilities that register with the FDA and must follow current good manufacturing practices (cGMP) for sterile drugs intended for office use or larger batches. These facilities face stricter quality controls but still cannot produce copies of approved drugs outside limited exceptions.
Tirzepatide, marketed by Lilly as Mounjaro (for diabetes) and Zepbound (for weight management and obstructive sleep apnea), became subject to high demand. The FDA placed certain formulations on its drug shortage list, temporarily allowing compounding pharmacies to produce versions under specific conditions. Once the FDA determined the shortages were resolved, compounding of exact copies became restricted. Lilly and regulators have argued that continued large-scale production of similar formulations exceeds the statutory exemptions for compounding.
Empower Pharmacy operates both 503A compounding services and 503B outsourcing facilities in Houston, Texas. The company has described itself as one of the nation’s largest compounding operations, with significant production capacity. It has faced prior regulatory scrutiny, including earlier FDA inspections noting compliance issues with sterile compounding standards.
Key Legal Issues Explained
At its core, the Empower Pharmacy lawsuit involves claims of false advertising under the federal Lanham Act and violations of state consumer protection statutes. Lilly alleges that Empower marketed compounded tirzepatide products, including an oral disintegrating tablet (Tirzepatide ODT) and a tirzepatide/niacinamide injectable combination, in ways that misled consumers. According to the complaint, Empower’s marketing implied these products were comparable in safety and efficacy to Lilly’s FDA-approved injectables, even though the compounded versions have not undergone the same premarket clinical testing required for new drugs.
Specific allegations include Empower’s use of references to Lilly’s clinical trial data (from studies on the injectable form) to promote its own oral and combination products, which differ in formulation, bioavailability, and administration. Lilly contends these products are not truly “personalized” but are mass-produced standardized formulations supplied to clinics and telehealth providers. The complaint further asserts that such practices create safety risks because compounded drugs are not subject to the same rigorous FDA review, labeling requirements, or adverse-event reporting as approved medications.
Empower has maintained that its operations comply with applicable compounding laws. It argues that physicians prescribe compounded tirzepatide for patients with individualized medical needs and that its formulations address supply gaps or preferences (such as needle-free options). The company has characterized the litigation as an effort by a brand manufacturer to limit competition and restrict patient access to more affordable alternatives.
Separately, the FDA issued warning letters to Empower in April 2025 following inspections of its Houston facilities. The letters cited deficiencies in sterile drug production practices, including insanitary conditions, inadequate environmental monitoring, failures in media fill simulations, and release of batches despite microbial concerns. These observations raised questions about whether certain products met the conditions for exemption under section 503B. Empower submitted responses outlining corrective actions, but the agency has continued to monitor compliance.
Latest Developments or Case Status
Eli Lilly filed the initial complaint on April 1, 2025, in the U.S. District Court for the District of New Jersey (Case No. 2:25-cv-02183). The suit named Empower Clinic Services, LLC d/b/a Empower Pharmacy and its New Jersey affiliate. On July 28, 2025, Lilly voluntarily dismissed the New Jersey action without prejudice and refiled substantially similar claims in the U.S. District Court for the Southern District of Texas (Case No. 4:25-cv-03464) on July 25, 2025.
In the Texas case, Empower filed a motion to dismiss in October 2025. The company argues that Lilly’s claims improperly seek private enforcement of the FDCA and that the lawsuit represents anticompetitive conduct aimed at eliminating lower-cost alternatives. As of April 2026, the motion remains pending before the court, and no trial date has been set. Discovery has been stayed pending resolution of the dismissal motion.
In parallel, the FDA’s ongoing oversight of Empower’s facilities continues, with follow-up inspections in early 2026 noting some repeat observations related to quality controls.
Who Is Affected and Potential Impact
Patients using or considering compounded GLP-1 medications represent the primary group affected. Many rely on these formulations for cost or availability reasons. Outcomes in the Empower Pharmacy lawsuit could influence the availability of such options nationwide. Healthcare providers who prescribe compounded drugs, compounding pharmacies, and telehealth platforms that partner with them may also face heightened compliance expectations.
Brand pharmaceutical companies like Lilly have an interest in protecting intellectual property and market exclusivity for drugs that underwent extensive clinical development. Regulatory agencies, including the FDA and state pharmacy boards, are tasked with balancing innovation and access against public health protections.
Potential consequences include injunctions limiting certain marketing practices, financial penalties if liability is established, or industry-wide shifts toward stricter adherence to compounding exemptions. Conversely, a ruling favorable to Empower could reinforce the role of compounding pharmacies in addressing ongoing medication access challenges.
What This Means Going Forward
The Empower Pharmacy lawsuit serves as a test case for the scope of permissible compounding in a post-shortage environment. It underscores the importance of clear distinctions between patient-specific compounding and commercial-scale production of drug copies. Courts will likely examine whether marketing claims cross into prohibited territory under the Lanham Act or state consumer laws.
Stakeholders should monitor federal court dockets for rulings on the motion to dismiss, as well as any FDA updates on warning letter resolutions or further enforcement actions. State pharmacy boards continue to review licensing and dispensing practices for out-of-state compounders. Patients are advised to consult their healthcare providers about the risks and benefits of any medication, including compounded formulations, and to verify sourcing from licensed, compliant pharmacies.
Frequently Asked Questions
What is the Empower Pharmacy lawsuit about?
The lawsuit, brought by Eli Lilly and Company, alleges that Empower Pharmacy unlawfully compounded and falsely marketed tirzepatide-based products as safe, effective, and personalized alternatives to FDA-approved Mounjaro and Zepbound after related drug shortages ended.
Is compounded tirzepatide still legal?
Compounded tirzepatide remains permissible under sections 503A and 503B of the FDCA when prepared pursuant to a valid patient-specific prescription and in compliance with statutory conditions. Large-scale production of copies of approved drugs outside shortage periods is restricted.
What are the main allegations in the complaint?
Lilly claims false advertising under the Lanham Act and violations of the New Jersey Consumer Fraud Act (in the original filing) through misleading statements about safety, efficacy, and personalization of untested compounded formulations.
Has the case been decided?
No. The matter is ongoing in the U.S. District Court for the Southern District of Texas. Empower’s motion to dismiss is pending as of April 2026.
What role did the FDA play?
The FDA resolved tirzepatide shortages, triggering restrictions on compounding copies, and issued warning letters to Empower in April 2025 regarding sterile manufacturing practices at its facilities.
Are patients at risk from compounded GLP-1 drugs?
The FDA has received reports of adverse events associated with compounded semaglutide and tirzepatide, often linked to dosing errors or quality issues. Patients should discuss individualized risks with their physicians.
Conclusion
The Empower Pharmacy lawsuit illustrates ongoing challenges in regulating compounded medications amid high demand for innovative therapies. It reflects broader efforts to ensure patient safety while preserving access to customized treatments. As the case progresses through federal court and regulatory oversight continues, interested parties should follow official court filings and FDA announcements for the most current information. This article is for informational purposes only and does not constitute legal advice. Individuals should consult qualified legal or healthcare professionals for advice specific to their circumstances.
You May Also Like: The Latest Tax Rise Lawsuit Update: What You Need to Know